Title : High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma.

Pub. Date : 2022 Jan

PMID : 34837846






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 MEK inhibitor showed synergy with multikinase inhibitor ponatinib, ABL inhibitor nilotinib, PI3K/mTOR inhibitor pictilisib, and pan-RAF inhibitor LY3009120. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens